Development of Hyperplasias, Preneoplasias, and Mammary Tumors in MMTV-c-erbB-2 and MMTV-TGFα Transgenic Rats

par Davies, Barry R., Platt-Higgins, Angela M., Schmidt, Gunter, Rudland, Philip S.
Publié 1999

Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

par Sommer, Eeva M., Dry, Hannah, Cross, Darren, Guichard, Sylvie, Davies, Barry R., Alessi, Dario R.
Publié 2013

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation

par Fox, Emily M, Kuba, María Gabriela, Miller, Todd W, Davies, Barry R, Arteaga, Carlos L
Publié 2013

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer

par De Velasco, Marco A., Kura, Yurie, Yoshikawa, Kazuhiro, Nishio, Kazuto, Davies, Barry R., Uemura, Hirotsugu
Publié dans Oncotarget (2016)

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer...

par CRAFTER, CLAIRE, VINCENT, JOHN P., TANG, ERIC, DUDLEY, PHILLIPPA, JAMES, NEIL H., KLINOWSKA, TERESA, DAVIES, BARRY R.
Publié dans Int J Oncol (2015)

Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response

par Floc'h, Nicolas, Guerriero, Maria Luisa, Ramos-Montoya, Antonio, Davies, Barry R., Cairns, Jonathan, Karp, Natasha A.
Publié dans Dis Model Mech (2018)

Transfection of S100A4 Produces Metastatic Variants of an Orthotopic Model of Bladder Cancer

par Levett, Diana, Flecknell, Paul A., Rudland, Philip S., Barraclough, Roger, Neal, David E., Mellon, J. Kilian, Davies, Barry R.
Publié 2002

Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells

par Dickstein, Rian J., Nitti, Giovanni, Dinney, Colin P., Davies, Barry R., Kamat, Ashish M., McConkey, David J.
Publié 2012

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen

par Lynch, James T., McEwen, Robert, Crafter, Claire, McDermott, Ultan, Garnett, Mathew J., Barry, Simon T., Davies, Barry R.
Publié dans Oncotarget (2016)

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors

par Feng, Shu, Shao, Longjiang, Castro, Patricia, Coleman, Ilsa, Nelson, Peter S, Smith, Paul D, Davies, Barry R, Ittmann, Michael
Publié dans Oncotarget (2016)

Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia

par Chapman, Elinor A., Oates, Melanie, Mohammad, Ishaque S., Davies, Barry R., Stockman, Paul K., Zhuang, Jianguo, Pettitt, Andrew R.
Publié dans Oncotarget (2017)

A pharmacokinetic–pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055

par Yates, James W T, Holt, Sarah V, Logie, Armelle, Payne, Kirsty, Woods, Karen, Wilkinson, Robert W, Davies, Barry R, Guichard, Sylvie M
Publié dans Br J Pharmacol (2017)

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma

par Ezell, Scott A., Wang, Suping, Bihani, Teeru, Lai, Zhongwu, Grosskurth, Shaun E., Tepsuporn, Suprawee, Davies, Barry R., Huszar, Dennis, Byth, Kate F.
Publié dans Oncotarget (2016)

Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment

par Searle, Emma J, Telfer, Brian A, Mukherjee, Debayan, Forster, Duncan M, Davies, Barry R, Williams, Kaye J, Stratford, Ian J, Illidge, Tim M
Publié dans EMBO Mol Med (2017)

Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer

par Butler, Dominika E., Marlein, Christopher, Walker, Hannah F., Frame, Fiona M., Mann, Vincent M., Simms, Matthew S., Davies, Barry R., Collins, Anne T., Maitland, Norman J.
Publié dans Oncotarget (2017)

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy

par O'Neill, Daniel, Jones, Dominic, Wade, Mark, Grey, James, Nakjang, Sirintra, Guo, Wenrui, Cork, David, Davies, Barry R., Wedge, Steve R., Robson, Craig N., Gaughan, Luke
Publié dans Oncotarget (2015)

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

par Li, Jing, Davies, Barry R, Han, Sufang, Zhou, Minhua, Bai, Yu, Zhang, Jingchuan, Xu, Yan, Tang, Lily, Wang, Huiying, Liu, Yuan Jie, Yin, Xiaolu, Ji, Qunsheng, Yu, De-Hua
Publié 2013

Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy

par De Velasco, Marco A., Kura, Yurie, Sakai, Kazuko, Hatanaka, Yuji, Davies, Barry R., Campbell, Hayley, Klein, Stephanie, Kim, Youngsoo, MacLeod, A. Robert, Sugimoto, Koichi, Yoshikawa, Kazuhiro, Nishio, Kazuto, Uemura, Hirotsugu
Publié dans JCI Insight (2019)

Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model

par Jiang, Yanyan, Martin, Jennifer, Alkadhimi, Maryam, Shigemori, Kay, Kinchesh, Paul, Gilchrist, Stuart, Kersemans, Veerle, Smart, Sean, Thompson, James M., Hill, Mark A., O’Connor, Mark J., Davies, Barry R., Ryan, Anderson J.
Publié dans Br J Cancer (2021)

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

par Green, Tim P., Fennell, Mike, Whittaker, Robin, Curwen, Jon, Jacobs, Vivien, Allen, Jack, Logie, Armelle, Hargreaves, Judith, Hickinson, D. Mark, Wilkinson, Robert W., Elvin, Paul, Boyer, Brigitte, Carragher, Neil, Plé, Patrick A., Bermingham, Alun, Holdgate, Geoffrey A., Ward, Walter H.J., Hennequin, Laurent F., Davies, Barry R., Costello, Gerard F.
Publié dans Mol Oncol (2009)